Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Beta Drugs's current ratio for the quarter that ended in Jun. 2026 was 0.00.
Beta Drugs has a current ratio of 0.00. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Beta Drugs has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Beta Drugs's Current Ratio or its related term are showing as below:
NSE:BETA'
s Current Ratio Range Over the Past 10 Years
Min: 1.16 Med: 1.99 Max: 3.22
Current: 3.1
During the past 13 years, Beta Drugs's highest Current Ratio was 3.22. The lowest was 1.16. And the median was 1.99.
NSE:BETA's Current Ratio is ranked better than 69.27% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs NSE:BETA: 3.10
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Beta Drugs Current Ratio Related Terms
Beta Drugs Current Ratio Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Current Ratio distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a Current Ratio of 0.00 as of Jun. 2026. Over the past decade, Beta Drugs' Current Ratio has ranged from 1.16 to 3.22. According to the industry distribution chart, Beta Drugs ranks #307 out of 999 companies in the Drug Manufacturers industry, placing it in the top 30.7%.
Is Beta Drugs' Current Ratio too high?
Beta Drugs' current Current Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 1.16 to a high of 3.22. Based on the distribution chart, Beta Drugs ranks #307 out of 999 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beta Drugs has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #307 out of 999 companies for Current Ratio. This puts Beta Drugs in the upper half of its industry. The industry median Current Ratio is 1.98. Historically, Beta Drugs' own Current Ratio has ranged from 1.16 to 3.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.98, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current Current Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,679.15, compared to a current price of ₹2,373.70 — trading 11.4% below its estimated fair value. The current Current Ratio is 0.00. Beta Drugs' overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Current Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be undervalued.
The current stock price of ₹2,373.70 is trading 11.4% below its estimated GF Value™ of ₹2,679.15.
GuruFocus considers Beta Drugs to be Modestly Undervalued.
Key valuation signals for NSE:BETA:
Current Ratio: 0.00
GF Value™: ₹2,679.15 vs. price of ₹2,373.70 (11.4% below fair value)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
90GF Score
Get the complete analysis for NSE:BETA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
